Calcitonin gene-related peptide in migraine : from pathophysiology to treatment
Copyright © 2019 Sociedad Española de Neurología. Published by Elsevier España, S.L.U. All rights reserved..
INTRODUCTION: It has been observed in recent years that levels of such molecules as calcitonin gene-related peptide (CGRP) and, to a lesser extent, the pituitary adenylate cyclase-activating peptide are elevated during migraine attacks and in chronic migraine, both in the cerebrospinal fluid and in the serum. Pharmacological reduction of these proteins is clinically significant, with an improvement in patients' migraines. It therefore seems logical that one of the main lines of migraine research should be based on the role of CGRP in the pathophysiology of this entity.
DEVELOPMENT: The Spanish Society of Neurology's Headache Study Group decided to draft this document in order to address the evidence on such important issues as the role of CGRP in the pathophysiology of migraine and the mechanism of action of monoclonal antibodies and gepants; and to critically analyse the results of different studies and the profile of patients eligible for treatment with monoclonal antibodies, and the impact in terms of pharmacoeconomics.
CONCLUSIONS: The clinical development of gepants, which are CGRP antagonists, for the acute treatment of migraine attacks, and CGRP ligand and receptor monoclonal antibodies offer promising results for these patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:37 |
|---|---|
| Enthalten in: |
Neurologia - 37(2022), 5 vom: 05. Juni, Seite 390-402 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Santos-Lasaosa, S [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 09.06.2022 Date Revised 09.06.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.nrleng.2019.03.025 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM341939331 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM341939331 | ||
| 003 | DE-627 | ||
| 005 | 20231226012925.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.nrleng.2019.03.025 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1139.xml |
| 035 | |a (DE-627)NLM341939331 | ||
| 035 | |a (NLM)35672126 | ||
| 035 | |a (PII)S2173-5808(21)00067-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Santos-Lasaosa, S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Calcitonin gene-related peptide in migraine |b from pathophysiology to treatment |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.06.2022 | ||
| 500 | |a Date Revised 09.06.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2019 Sociedad Española de Neurología. Published by Elsevier España, S.L.U. All rights reserved. | ||
| 520 | |a INTRODUCTION: It has been observed in recent years that levels of such molecules as calcitonin gene-related peptide (CGRP) and, to a lesser extent, the pituitary adenylate cyclase-activating peptide are elevated during migraine attacks and in chronic migraine, both in the cerebrospinal fluid and in the serum. Pharmacological reduction of these proteins is clinically significant, with an improvement in patients' migraines. It therefore seems logical that one of the main lines of migraine research should be based on the role of CGRP in the pathophysiology of this entity | ||
| 520 | |a DEVELOPMENT: The Spanish Society of Neurology's Headache Study Group decided to draft this document in order to address the evidence on such important issues as the role of CGRP in the pathophysiology of migraine and the mechanism of action of monoclonal antibodies and gepants; and to critically analyse the results of different studies and the profile of patients eligible for treatment with monoclonal antibodies, and the impact in terms of pharmacoeconomics | ||
| 520 | |a CONCLUSIONS: The clinical development of gepants, which are CGRP antagonists, for the acute treatment of migraine attacks, and CGRP ligand and receptor monoclonal antibodies offer promising results for these patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Anticuerpos monoclonales | |
| 650 | 4 | |a CGRP | |
| 650 | 4 | |a Chronic migraine | |
| 650 | 4 | |a Gepantes | |
| 650 | 4 | |a Gepants | |
| 650 | 4 | |a Migraine | |
| 650 | 4 | |a Migraña | |
| 650 | 4 | |a Migraña crónica | |
| 650 | 4 | |a Monoclonal antibodies | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Calcitonin Gene-Related Peptide Receptor Antagonists |2 NLM | |
| 650 | 7 | |a Calcitonin Gene-Related Peptide |2 NLM | |
| 650 | 7 | |a JHB2QIZ69Z |2 NLM | |
| 700 | 1 | |a Belvís, R |e verfasserin |4 aut | |
| 700 | 1 | |a Cuadrado, M L |e verfasserin |4 aut | |
| 700 | 1 | |a Díaz-Insa, S |e verfasserin |4 aut | |
| 700 | 1 | |a Gago-Veiga, A |e verfasserin |4 aut | |
| 700 | 1 | |a Guerrero-Peral, A L |e verfasserin |4 aut | |
| 700 | 1 | |a Huerta, M |e verfasserin |4 aut | |
| 700 | 1 | |a Irimia, P |e verfasserin |4 aut | |
| 700 | 1 | |a Láinez, J M |e verfasserin |4 aut | |
| 700 | 1 | |a Latorre, G |e verfasserin |4 aut | |
| 700 | 1 | |a Leira, R |e verfasserin |4 aut | |
| 700 | 1 | |a Pascual, J |e verfasserin |4 aut | |
| 700 | 1 | |a Porta-Etessam, J |e verfasserin |4 aut | |
| 700 | 1 | |a Sánchez Del Río, M |e verfasserin |4 aut | |
| 700 | 1 | |a Viguera, J |e verfasserin |4 aut | |
| 700 | 1 | |a Pozo-Rosich, P |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Neurologia |d 2007 |g 37(2022), 5 vom: 05. Juni, Seite 390-402 |w (DE-627)NLM171204786 |x 2173-5808 |7 nnns |
| 773 | 1 | 8 | |g volume:37 |g year:2022 |g number:5 |g day:05 |g month:06 |g pages:390-402 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.nrleng.2019.03.025 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 37 |j 2022 |e 5 |b 05 |c 06 |h 390-402 | ||